Aprea Therapeutics gets Nasdaq extension to regain $1 minimum bid price compliance
APRE•Nasdaq grants second compliance period
Aprea Therapeutics received a Nasdaq notice granting a second 180-day window to regain $1 minimum bid-price compliance.
The new deadline is Jan. 19, 2027; shares must close at $1 or higher for 10 consecutive business days to cure.
Failure to regain compliance by the deadline triggers a delisting notice; the company can appeal to a Nasdaq hearings panel.
